NEVRO CORP
NVROHealthcare · Surgical & Medical Instruments & Apparatus · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $408.5M | $425.2M | $406.4M | $386.9M | $362.0M | $390.3M |
| Operating income | −$126.2M | −$99.3M | $6.2M | −$110.9M | −$62.9M | −$96.5M |
| Net income | −$113.4M | −$92.2M | $3.0M | −$131.4M | −$83.1M | −$103.7M |
| Total assets | $553.8M | $635.7M | $602.4M | $574.5M | $789.4M | $469.6M |
| Total liabilities | $322.8M | $342.6M | $278.5M | $270.9M | $401.0M | $253.3M |
| Equity | $231.0M | $293.1M | $323.9M | $303.6M | $388.5M | $216.4M |
| EPS (diluted) | $-3.06 | $-2.56 | $0.08 | $-3.77 | $-2.47 | — |
| Shares out. | 36.4M | 35.5M | 35.0M | 34.6M | 31.8M | 30.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −30.9%
- Net margin
- −27.8%
- Return on equity
- −49.1%
- Return on assets
- −20.5%
- Return on capital (ROCE)
- −28.0%
- Liabilities / assets
- 58.3%
- Debt / equity
- 1.40×
- Book value / share
- $6.35
- Revenue growth (YoY)
- −3.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -1.15distress
- Accruals / assets
- −17.0%clean
- Beneish M-Score
- -3.48normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Beryl Capital Management LlcPassive (13G)Aug 14, 2025
- Goldman Sachs Group IncPassive (13G)Aug 13, 2025
- Arrowmark Colorado Holdings LlcPassive (13G)May 15, 2025
- Gamco Investors, Inc. Et AlActivist (13D)Apr 4, 2025
- Shay Capital LlcPassive (13G)Feb 14, 2025
- Armistice Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Grossman D KeithDirector | Apr 3, 2025 | D | 228,552 | — |
| Kosaraju SridharDirector | Apr 3, 2025 | D | 46,575 | — |
| Mccormick ShawnDirector | Apr 3, 2025 | D | 46,035 | — |
| Siegel Susan EDirector | Apr 3, 2025 | D | 24,579 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Mar 31, 2025 | 1.0M | 1.0 | -39.3% |
| Mar 14, 2025 | 1.7M | 1.5 | -7.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventApr 3, 2025
- Shareholder voteApr 2, 2025
- Results of operationsMar 4, 2025
- Entered a material agreement · Regulation FD disclosure · Other material eventFeb 6, 2025
- Results of operationsJan 14, 2025
- Results of operations · Regulation FD disclosureNov 14, 2024
- Results of operationsAug 6, 2024
- Shareholder voteMay 29, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AAug 14, 2025
- SCHEDULE 13G/AAug 13, 2025
- SCHEDULE 13G/AMay 15, 2025
- SCHEDULE 13GMay 13, 2025
- 15-12GApr 14, 2025
- EFFECTApr 7, 2025
- SCHEDULE 13D/AApr 4, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
- 4Apr 3, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.